Global Phenobarbital Market: Introduction

Phenobarbital is a long-acting barbiturate, an anti-epileptic medication (AED) that sedates the nervous system. It is generally prescribed by health care professionals to avoid seizures or to ease anxiety. Phenobarbital is often recommended to treat disorders such as epilepsy and seizure because the drug stabilizes electrical activity in the brain. Phenobarbital is a drug class known as anticonvulsants /hypnotics barbiturate. This medication is also used for a brief period of time (generally not more than 2 weeks) to assist individuals to calm down or help them sleep during anxiety periods. It operates to trigger calming by influencing certain components of the brain. Phenobarbital is taken by mouth in the form of tablet or an elixir (liquid). Usually, its dosage is one to three times a day.

View Report : https://www.transparencymarketresearch.com/phenobarbital-market.html

Global Phenobarbital Market: Competitive Landscape

Novartis AG

Founded in 1996, Novartis AG is among the top global pharmaceutical companies operating across all the regions in almost all the specialties. Novartis operates in patented pharmaceutical products, generic pharmaceuticals & biosimilars, and surgical and vision care segments. It offers many OTC as well as generic drugs for acute attack treatment of migraine. The company is investing into specialty prophylactic treatment drugs through its recent acquisitions and strategic collaborations.

Sanofi S.A.

Incorporated in 2004, Sanofi, formerly Sanofi-Aventis, is a health care corporation involved in the research, development, production, and marketing of therapeutic solutions. The company operates through three major business segments: Vaccines, Pharmaceuticals, and Animal Health Care.

Other key players operating in the global Phenobarbital market include AstraZeneca Plc., Allergan Plc., GlaxoSmithKline Plc., Eli Lilly & Company, Merck & Co., Inc., Arrow Pharmaceuticals, Janssen Pharmaceutical Company (Johnson & Johnson),  and Dainippon Sumitomo Pharma. 

For More Details, Request A PDF Brochure Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=71679&ltype=S

Global Phenobarbital Market: Dynamics

High Prevalence of Epilepsy to Drive Market

Epilepsy is a chronic neurological disorder with approximately 50 million patient population. The growing incidence of illnesses is expected to increase the demand for epilepsy treatment and hence, the phenobarbital market.

Rise in Geriatric Population to Boost Market

Epilepsy is common among both kids and adults. However, elderly population is more likely to be impacted by this disorder. It is predicted that increase in geriatric population is likely to increase demand for epilepsy treatment. This, in turn, is expected to boost the phenobarbital market in the next few years.

Global Phenobarbital Market: Segmentation

The global phenobarbital market can be segmented based on:

• Indications
• Route of Administration
• Distribution Channel

Global Phenobarbital Market, by Indications

In terms of indications, the global phenobarbital market can be divided into:

• Epileptic Seizures
• Anxiety
• Others

Global Phenobarbital Market, by Route of Administration

Based on route of administration, the global phenobarbital market can be classified into:

• Oral
• Injectable
• Others

Buy  Now This Report : https://www.transparencymarketresearch.com/checkout.php?rep_id=71679&ltype=S

Global Phenobarbital Market, by Distribution Channel

In terms of distribution channel, the global phenobarbital market can be segregated into:

• Hospitals Pharmacies
• Retail Pharmacies
• Others (online pharmacies, drug stores)